solriamfetol
Adjunctive therapy • Brands: Sunosi
Last reviewed: 2026-02-12
General information
- Class: Adjunctive therapy
- Common US brands: Sunosi
- Therapeutic drug monitoring not routinely recommended.
- Last reviewed: 2026-02-12
Dosing & forms
- Forms/strengths: —
- Frequency: —
- Food: —
- Typical range: —
Mechanism (brief)
Wakefulness-promoting dopamine and norepinephrine reuptake inhibitor (solriamfetol) indicated to improve wakefulness in adults with excessive sleepiness associated with narcolepsy or obstructive sleep apnea; Schedule IV with dose-dependent blood pressure/heart rate effects and MAOI contraindication.
Metabolism & Half‑life
- Metabolism: Minimal metabolism (minor inactive N-acetyl metabolite)
- Half‑life: Single-dose mean 7.1 h
Therapeutic Drug Monitoring (TDM)
Recommended: No
Monitoring highlights
- —
Sources
- SUNOSI (solriamfetol) tablets prescribing information — DailyMed (2026)
- Treatment of central disorders of hypersomnolence: an American Academy of Sleep Medicine clinical practice guideline — Journal of Clinical Sleep Medicine (2021)
- Treatment of central disorders of hypersomnolence: an American Academy of Sleep Medicine systematic review, meta-analysis, and GRADE assessment — Journal of Clinical Sleep Medicine (2021)
- A randomized study of solriamfetol for excessive sleepiness in narcolepsy — Annals of Neurology (2019)
- Solriamfetol for Excessive Sleepiness in Obstructive Sleep Apnea (TONES 3). A Randomized Controlled Trial — American Journal of Respiratory and Critical Care Medicine (2019)